Tabrecta (capmatinib) / Incyte, Novartis - LARVOL DELTA

The Efficacy of Capmatinib in Treating NSCLC Patients With MET Amplification in a Multi-Center Real-World Setting (IASLC-WCLC 2025) - "The MET GCN holds potential as a biomarker for predicting the efficacy of capmatinib in treating patients with MET amplification. Moreover, the fact that adverse events are manageable further validates its application in clinical practice."

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • MET

Real-World Outcomes of Full and Reduced Dose Capmatinib and Tepotinib Treatment for MET Exon 14 Skipping Mutation NSCLC (IASLC-WCLC 2025) - "41 (95%) patients had not previously received MET targeted therapy, 2 had received crizotinib. Median PFS is similar to previous real-world analysis (Correia et al, JCO 2024). These data suggest that in older patients, often with comorbidities, or patients with AE necessitating dose reduction, patients have similar benefit to MET TKI."

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • MET

A Realworld Study: Clinical Molecular Characteristics and Prognostic Factors of NSCLC With MET Alteration (IASLC-WCLC 2025) - "While MET tyrosine kinase inhibitors (TKIs) like capmatinib and savolitinib are FDA-approved for METex14-altered NSCLC, their efficacy in primary MET-amplified disease remains under investigation...Next-generation MET-TKIs (e.g., savolitinib) show improved efficacy over crizotinib, particularly in METex14-mutated cases. TP53 co-mutations and treatment timing critically influence survival, highlighting the need for biomarker-guided therapeutic strategies. These findings underscore the need for optimized therapeutic strategies in MET-driven NSCLC."

Biomarker • Clinical • IO biomarker • Real-world • Real-world evidence • Fatigue • Hepatology • Liver Failure • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • MET • TP53

Analysis of the Nationwide Database on the Penetration Rate of Lung Cancer Biomarker Tests in Japan (IASLC-WCLC 2025) - "For example, although Tepotinib and Capmatinib were launched in June 2020 and August 2020, respectively, the CDx rate for METex14sk remained around 10% until January 2022, when AmoyDx received insurance coverage for CDx testing of Tepotinib. Following this approval, the CDx rate increased to approximately 30%. Conclusions : Our study shows that driver gene searches using multiple diagnostics are becoming more widespread in Japan in 2019 compared to 2024."

Biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • HER-2 • KRAS • NTRK • ROS1

Patient-Derived Organoids as Preclinical Models for Drug Resistance in NSCLC (IASLC-WCLC 2025) - "These patients were resistant to TKI inhibitors, including Afatinib, Capmatinib, Gefitinib, Amivantamab, and Trastuzumab. The high concordance between PDO drug screening and patient responses highlights the potential of these models to guide personalized treatment decisions. Additionally, the scalability and rapid establishment of PDOs make them well-suited for high-throughput and synthetic lethality screening, offering a promising platform for identifying novel therapeutic strategies in TKI-resistant NSCLC."

Preclinical • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR • HER-2 • KRAS • MET • NTRK • ROS1

Activity and Tolerability of MET Tkis in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database (IASLC-WCLC 2025) - "Introduction : Capmatinib and tepotinib have been incorporated into the treatment algorithm for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations (METex14). This updated real-world analysis confirmed the good clinical activity of MET TKIs, particularly in the treatment-naive setting, supporting the implementation of this therapeutic approach in a challenging patient population. 1 Reale ML, et al. ESMO Open."

Biomarker • Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Solid Tumor • MET

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib. (PubMed, J Pharm Biomed Anal) - "After the validation, 74 plasma samples were measured in the application phase and all results but one fell within the validated ranges. This assay allows simultaneous quantification of nine novel targeted therapies and supports therapeutic drug monitoring."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies. (PubMed, Target Oncol) - "This review summarizes the frequency of MET alterations across different cancer types and the clinical validation of MET alterations in MET-targeted therapies, offering a detailed comparison of objective response rates (ORR) for therapies including crizotinib, capmatinib, tepotinib, savolitinib, telisotuzumab vedotin, telisotuzumab adizutecan, and amivantamab. Additionally, emerging technologies such as circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) analyses have been investigated for their potential to improve MET alterations detection. This review also highlights studies that demonstrate the potential of MET ctDNA and CTC analyses to predict treatment responses and identify resistance mechanisms in MET-targeted therapies."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (clinicaltrials.gov) - P1 | N=105 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Oct 2025 ➔ Mar 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

…Novartis…announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication (flcube.com) - "The drug is now licensed to treat adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations."

China approval • Non Small Cell Lung Cancer

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. (clinicaltrials.gov) - P4 | N=50 | Completed | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Completed

Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • MET

The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review. (PubMed, Transl Lung Cancer Res) - "Furthermore, capmatinib and tepotinib demonstrate extraordinary efficacy for patients with NSCLC and MET exon 14 (METex14) skipping mutation, and the combination of capmatinib and gefitinib in particular can achieve remarkable therapeutic effects in patients with EGFR-mutated, MET-dysregulated (amplified/overexpressing) NSCLC. The administration of capmatinib can help mitigate potential food-intake and drug-drug interactions in clinical settings. This facilitates the optimization of long-term medication schedules, enhancing the clinical efficacy of the treatment."

Journal • PK/PD data • Review • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Low-energy room-temperature carbon dots for targeted sensing of MET inhibitor capmatinib. (PubMed, RSC Adv) - "Recovery studies in real biological samples yielded rates between 97.4% and 105.3%, and RSDs were consistently below 4.11%. These results demonstrate the method's precision, reproducibility, and potential for reliable CMB detection in complex biological matrices."

Journal

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone (clinicaltrials.gov) - P2 | N=29 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Solid Tumor

Evolving roles of MET as a therapeutic target in NSCLC and beyond. (PubMed, Nat Rev Clin Oncol) - "To date, the MET tyrosine-kinase inhibitors (TKIs) capmatinib, tepotinib and savolitinib have been approved for the treatment of advanced-stage METex14-mutant NSCLC...Indeed, in May 2025, the MET-directed ADC telisotuzumab vedotin was approved by the FDA for patients with previously treated advanced-stage nonsquamous NSCLC overexpressing MET (≥50% of tumour cells with 3+ staining on immunohistochemistry). Understanding the unique MET-related adverse events will be crucial when incorporating these agents into daily clinical practice. In this Review, we highlight the rationale for targeting MET alterations across various solid tumour types and provide a summary of the clinical efficacy and toxicity profiles of the approved and emerging MET-targeted TKIs, monoclonal or bispecific antibodies and ADCs."

Journal • Review • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Capmatinib treatment in a patient with osimertinib-resistant NSCLC harboring two distinct MET alterations revealed by tissue-based NGS testing. (PubMed, Cancer Pathog Ther) - No abstract available

Journal • Next-generation sequencing • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Crosstalk between oncogenic signaling pathways as driver of therapy resistance against small molecule inhibitors in Glioblastoma (EACR 2025) - "Result and SMIs targeting downstream effector kinases (Trametinib, Buparlisib, Abemaciclib; IC50 70nM-1µM) or membrane-bound tyrosine kinase receptors (Afatinib, Capmatinib, Axitinib; IC50 1-15µM) reduced cell viability...Combined trametinib and SP600125 (JNKi) mitigated JNK/c-Jun activation and synergistically reduced cell viability (Bliss >20), but failed to suppress MEKSer221 hyperphosphorylation... Trametinib reduces cell viability but triggers compensatory signaling, including MEKSer221 hyperphosphorylation. This study presents a mechanistically driven selection of tumor-tailored combination treatments to overcome resistance to SMI monotherapy in pdGBM models, highlighting VEGFR co-inhibition as a promising combinatorial strategy with trametinib."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy. (PubMed, Anticancer Res) - "PHA665752 combined with MTX synergistically inhibits OS cell growth via dual suppression of c-Met signaling (PI3K/AKT, MAPK/ERK). and MTX-mediated cytotoxicity, highlighting the potential of co-targeting overlapping pathways to enhance OS treatment efficacy."

Heterogeneity • Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NOS1

METalmark: A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=57 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Aug 2026 ➔ Apr 2026

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment. (PubMed, Front Pharmacol) - "Similarly, pharmacological targeting of the HGF/c-MET pathway with the inhibitor capmatinib markedly suppressed the activation of pro-survival signaling pathways, reduced the expression of anti-apoptotic proteins, inhibited cell proliferation, arrested cell cycle at G0/G1 stage, induced apoptosis, and enhanced the pro-apoptotic effect of ABT-199. In summary, this study highlights the critical role of HGF/c-MET axis in CLL cell survival and demonstrates that targeting this pathway holds therapeutic potential for the treatment of CLL."

IO biomarker • Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • BCL2 • BCL2L1 • MCL1 • MET

Molecular Profiling: Genomic-Guided Therapy for Lung Adenocarcinoma. (PubMed, Cureus) - "Capmatinib demonstrated durable disease control and was well tolerated, offering a viable alternative to conventional chemotherapy in an elderly patient with significant comorbidities. These findings support the integration of precision oncology into the management of advanced NSCLC and underscore the potential of MET TKIs to improve outcomes in this high-risk subgroup."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • MET

GeoMETry-C: Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (clinicaltrials.gov) - P2 | N=37 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • MET

Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database. (PubMed, Clin Epidemiol) - "Notably, unexpected SOC "Ear and labyrinth disorders" and PTs "hypoacusis" and "deafness" were identified, without being specified in the drug label. Our study identified unexpected ADRs associated with Capmatinib, with a focus on ototoxicity-related events, underscoring the need for enhanced clinical monitoring and further investigation into the underlying mechanisms."

Adverse events • Journal • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Otorhinolaryngology • Solid Tumor • MET

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma. (PubMed, JTO Clin Res Rep) - "This retrospective cohort study included patients with advanced EGFR-mutant LUAD who progressed after EGFR TKIs and were treated with combination therapy of EGFR TKIs and MET TKIs (capmatinib or tepotinib). Those with positive METamp had significantly longer median progression-free survival than those without (25.3 versus 5.8 mo; p = 0.034). The TKI combination reported clinical activities in patients with advanced EGFR-mutant LUAD resistant to EGFR TKIs and mild toxicity in those with MET overexpression."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET • TP53

Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14–skipping+ NSCLC. (ASCO 2025) - "In this real-world cohort of METex14+ treated with dose-reduced cap/tep, clinical outcomes were encouraging. Dose-reduction and, in some cases, unorthodox dosing schedules allowed for mitigation of toxicity and continuation of therapy. Low rates of CNS-only PD in the dose-reduced cohort suggest encouraging CNS penetrance."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Fatigue • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • MET